URGNUroGen Pharma Ltd.
Price
+105%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, growing in the filings, the market undecided.
We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
UroGen Pharma Ltd. (URGN) reported revenue of $72M in Q2 2026 (quarter ended Jun 30, 2026), up 199% from the same quarter a year earlier. That came with a gross margin of 91% and net loss of $14M. For the full year FY2025, revenue was $110M (+21% year on year) and net income −$153M. Its largest product in Q2 2026 was Zusduri at $50M, 70% of the disclosed total, well ahead of Jelmyto at 30%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 20, 2026On August 18, 2026, UroGen Pharma Ltd. (“the Company”), through its wholly owned subsidiary UroGen Pharma, Inc. (“UroGen U.S.”), entered into an Option and Research License Agreement (the “Option Agreement”) with IntraGel Therapeutics, Ltd. (“IntraGel”), a company organized under the laws of Israel.Other event · Form 8-K
- Aug 5, 2026UroGen Reports $50.4 Million of ZUSDURI ® Revenue and Provides Second Quarter 2026 Financial Results and Highlights.Earnings release · press release
- Jun 23, 2026At the Annual Meeting, the Company’s shareholders also approved (i) an amendment to the Company’s Amended and Restated Non-Employee Director and Officer Compensation Policy in relation to directors’ and officers’ insurance (the “Compensation Policy Amendment”) and (ii) an amendment to the Company’s 2017 Equity …Shareholder rights modified · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $72.5MThe company’s own SEC segment disclosure.
- Zusduri$50.4M70%
- Jelmyto$22.0M30%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.